Literature DB >> 22445204

Why thioridazine in combination with antibiotics cures extensively drug-resistant Mycobacterium tuberculosis infections.

Leonard Amaral1, Miguel Viveiros.   

Abstract

Thioridazine (TDZ) in combination with antibiotics to which extensively drug-resistant Mycobacterium tuberculosis (XDR-TB) is initially resistant yields a cure. This is due to the fact that TDZ enhances the killing of intracellular M. tuberculosis by non-killing macrophages, inhibits the genetic expression of efflux pumps of M. tuberculosis that extrude antibiotics prior to reaching their intended targets, and inhibits the activity of existing efflux pumps that contribute to the multidrug-resistant phenotype of M. tuberculosis. The combination of these effects of TDZ probably contributes to the successful recent cures of XDR-TB cases when the phenothiazine TDZ is used in combination with antibiotics to which the patient with XDR-TB was initially unresponsive.
Copyright © 2012 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22445204     DOI: 10.1016/j.ijantimicag.2012.01.012

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  18 in total

1.  Advances in the treatment of pulmonary tuberculosis.

Authors:  Xia Zhang; Jing Guo
Journal:  J Thorac Dis       Date:  2012-12       Impact factor: 2.895

2.  Thioridazine inhibits gene expression control of the cell wall signaling pathway (CWI) in the human pathogenic fungus Paracoccidioides brasiliensis.

Authors:  Daniela Leite Jabes; Ana Claudia de Freitas Oliveira; Valquíria Campos Alencar; Fabiano Bezerra Menegidio; Débora Liliane Souza Reno; Daiene Souza Santos; David Aciole Barbosa; Renata Ozelami Vilas Boas; Rodrigo Luiz de Oliveira Rodrigues Cunha; Tiago Rodrigues; Regina Costa de Oliveira; Luiz R Nunes
Journal:  Mol Genet Genomics       Date:  2016-03-08       Impact factor: 3.291

3.  Structural insights into xenobiotic and inhibitor binding to human aldehyde oxidase.

Authors:  Catarina Coelho; Alessandro Foti; Tobias Hartmann; Teresa Santos-Silva; Silke Leimkühler; Maria João Romão
Journal:  Nat Chem Biol       Date:  2015-08-31       Impact factor: 15.040

Review 4.  Novel adjunctive therapies for the treatment of tuberculosis.

Authors:  A A Ordonez; M Maiga; S Gupta; E A Weinstein; W R Bishai; S K Jain
Journal:  Curr Mol Med       Date:  2014-03       Impact factor: 2.222

Review 5.  Combination approaches to combat multidrug-resistant bacteria.

Authors:  Roberta J Worthington; Christian Melander
Journal:  Trends Biotechnol       Date:  2013-01-18       Impact factor: 19.536

Review 6.  WHO group 5 drugs and difficult multidrug-resistant tuberculosis: a systematic review with cohort analysis and meta-analysis.

Authors:  Kwok-Chiu Chang; Wing-Wai Yew; Cheuk-Ming Tam; Chi-Chiu Leung
Journal:  Antimicrob Agents Chemother       Date:  2013-06-17       Impact factor: 5.191

Review 7.  Repurposing drugs for treatment of tuberculosis: a role for non-steroidal anti-inflammatory drugs.

Authors:  Arundhati Maitra; Sadé Bates; Monisha Shaik; Dimitrios Evangelopoulos; Ibrahim Abubakar; Timothy D McHugh; Marc Lipman; Sanjib Bhakta
Journal:  Br Med Bull       Date:  2016-05-05       Impact factor: 4.291

8.  Effect of thioridazine on erythrocytes.

Authors:  Elisabeth Lang; Paola Modicano; Markus Arnold; Rosi Bissinger; Caterina Faggio; Majed Abed; Florian Lang
Journal:  Toxins (Basel)       Date:  2013-10-23       Impact factor: 4.546

9.  Antitubercular pharmacodynamics of phenothiazines.

Authors:  Ashley J Warman; Teresa S Rito; Nicholas E Fisher; Darren M Moss; Neil G Berry; Paul M O'Neill; Stephen A Ward; Giancarlo A Biagini
Journal:  J Antimicrob Chemother       Date:  2012-12-09       Impact factor: 5.790

10.  Efflux pumps of Gram-negative bacteria: what they do, how they do it, with what and how to deal with them.

Authors:  Leonard Amaral; Ana Martins; Gabriella Spengler; Joseph Molnar
Journal:  Front Pharmacol       Date:  2014-01-03       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.